Market closedNon-fractionalADR
Renalytix/RNLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Renalytix
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Ticker
RNLX
Sector
Healthcare
Trading on
NASDAQ
Industry
Software & Programming
Headquarters
London, United Kingdom
Employees
102
Website
renalytix.com
Renalytix Metrics
BasicAdvanced
$32M
Market cap
-
P/E ratio
-$0.78
EPS
2.89
Beta
-
Dividend rate
Price and volume
Market cap
$32M
Beta
2.89
52-week high
$4.04
52-week low
$0.24
Average daily volume
16
Financial strength
Current ratio
0.423
Interest coverage (TTM)
-8.74%
Management effectiveness
Return on assets (TTM)
-154.36%
Return on equity (TTM)
-1,073.18%
Return on investment (TTM)
-396.70%
Valuation
Price to revenue (TTM)
14.609
Growth
Revenue change (TTM)
-40.23%
Earnings per share change (TTM)
23.08%
What the Analysts think about Renalytix
Analyst Ratings
Majority rating from 2 analysts.
Renalytix Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$500K
-28.57%
Net income
-$7.7M
-8.33%
Profit margin
-1,540.00%
28.33%
Renalytix Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.24
-$0.22
-$0.18
-$0.08
-
Expected
-$0.13
-$0.10
-$0.09
-$0.08
-$0.08
Surprise
89.47%
120.00%
100.00%
6.67%
-
Renalytix News
AllArticlesVideos
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
GlobeNewsWire·2 weeks ago
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
GlobeNewsWire·4 weeks ago
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Renalytix stock?
Renalytix (RNLX) has a market cap of $32M as of July 27, 2024.
What is the P/E ratio for Renalytix stock?
The price to earnings (P/E) ratio for Renalytix (RNLX) stock is 0 as of July 27, 2024.
Does Renalytix stock pay dividends?
No, Renalytix (RNLX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Renalytix dividend payment date?
Renalytix (RNLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Renalytix?
Renalytix (RNLX) has a beta rating of 2.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Renalytix stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.